Healthcare / Medical DevicesStockholm
$3.92
-0.13 (-3.21%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-71.4M · quality 71.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$434M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-16.4%
↓Gross Margin
96.3%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+46.8%
FCF CAGR
—
FCF margin
-39.7%
FCF / Net income
1.40x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $180.2M · net income $-51.0M · FCF $-71.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $180.2M | $180.2M | $133.9M | $112.2M | $57.0M |
| Net Income | $-51.0M | $-51.0M | $-49.7M | $-130.5M | $-99.4M |
| EBITDA | $-46.0M | $-46.0M | $-42.0M | $-102.6M | $-80.5M |
| EPS | -0.48 | -0.48 | -0.51 | -1.59 | -1.70 |
| Gross Margin | 96.3% | 96.3% | 95.4% | 74.6% | 61.4% |
| Operating Margin | -26.8% | -26.8% | -36.9% | -82.0% | -170.1% |
| Net Margin | -28.3% | -28.3% | -37.1% | -116.3% | -174.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.01 | 0.01 | 0.05 |
| Current Ratio | 8.33 | 8.33 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-71.4M | $-71.4M | $-63.0M | $-94.0M | $-86.3M |
| Returns | |||||
| ROE | -16.4% | -16.4% | -23.2% | -52.0% | -40.1% |
| Valuation | |||||
| P/B | 1.33 | 1.33 | 4.80 | 2.89 | 1.51 |
| Growth & Yield | |||||
| Revenue Growth | 34.5% | 34.5% | 19.4% | 96.8% | — |
| EPS Growth | 5.9% | 5.9% | 67.9% | 6.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-69.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.51 → -0.48
Residual
-69.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.